Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wizz Air surges on Jan passenger numbers, route reinstatement

(Sharecast News) - Shares in Wizz Air surged on Friday as the low-cost airline reinstated routes to the Middle East and reported a 14.2% rise in January passenger numbers but load factor fell due to the conflict in Gaza and an increase in one-way traffic. The budget carrier on Friday said it carried 4.74 million passengers at a load factor of 82.0%, down 4.4 percentage points.

Load factor measures the percentage of available seating capacity that has been filled with passengers.

"Wizz Air is actively implementing measures to optimize our network and adapt to these dynamic conditions, with the aim of enhancing efficiency and supporting a recovery in load factors going forward," the company said.

It reinstated flights between Aqaba (Jordan) and Abu Dhabi, starting from February 4 and announced it would restart operations into Tel Aviv in Israel, with routes from Budapest, Sofia, Bucharest, Krakow, London and Rome opening from the beginning of March.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.